Searched for
MONTELUKAST SODIUM
Paracetamol to PAN-D: CDSCO finds over 50 sub-standard drugs. Check full list of medicinesThe Central Drugs Standard Control Organisation (CDSCO) has flagged over 50 drugs, including Paracetamol, as 'not of standard quality'. The...- Relief for pharma companies as API prices see a sharp fallIndia's pharmaceutical industry, which is dependent on China for APIs, intermediates and bulk drugs, had seen an exponential price increase...
- NPPA tells chief secys to keep tabs on API availabilityIn a letter to the chief secretaries, the National Pharmaceutical Pricing Authority (NPPA) has asked them to ensure that there is no violat...
- Covid-19 Impact: Pharma companies feel the pain as prices of key inputs shoot upAccording to the data available with Pharmaceutical Export Promotion Council (Pharmexcil), the cost of paracetamol has gone up from Rs 250-...
- Morepen Labs gets USFDA nod for asthma drugMorepen is the market leader for Montelukast in India with over 50 per cent market share, supplying to almost all major finished dosage man...
- Aurobindo Pharma, Cadila recall drugs from US marketPantoprazole Sodium delayed-release tablets are used for treatment of erosive inflammation of the esophagus due to acid reflux.
- Morepen to sell anti-asthmatic drug Montelukast in Europe, North AmericaPharma firm Morepen Laboratories today said it is preparing to sell anti-asthmatic drug Montelukast in European and North American markets.
- Ajanta Pharma launches generic asthma treatment tablets in USAjanta Pharma has launched its generic Montelukast Sodium tablets used for treatment of asthma and seasonal allergies in the American marke...
- Unichem gets USFDA nod for generic asthma treatment tabletsDrug firm Unichem Laboratories has received approval from the US health regulator for its Montelukast Sodium tablets used in prevention and...
- Ajanta Pharma gets USFDA nod for generic asthma treatment drugDrug firm Ajanta Pharma has received final approvals from the US health regulator for generic montelukast tablets and oral granules.
- Ten stocks in focus in Tuesday's tradeIndian markets are expected to trade in a range. Here is a list of ten stocks which are likely to be in focus today.
- Jubilant Life gets USFDA nod for generic anti-asthma tablets"This includes 72 ANDAs filed in the US, of which 35 have been approved and 46 dossier filings in Europe. So far, we have received 10 ANDA ...
- Pharmaceutical exports slow down due to approval delays and recallsThis is the first time in the recent years that the Indian pharma exports saw single digit growth in dollar terms.
- Glenmark recalls three drugs from US marketGlenmark Generics is recalling multiple lots of three of its drugs from the US market due to "odd smell", according to US FDA.
- Glenmark Generics recalls anti-asthma drug from US marketGlenmark Generics is recalling from the US market multiple lots of Montelukast Sodium tablets (10 mg) on "off-odour" complaints.
- Dr Reddy's Laboratories launches generic anti-asthma drug in US marketDr Reddy's Laboratories has launched its generic Montelukast Sodium oral granules used for treating asthma and seasonal allergies in the US...
- Aurobindo Pharma, Glenmark get FDA nod for generic montelukast sodium tabletsNew Delhi Drug firms Aurobindo Pharma and Glenmark have received approval from the US health regulator to manufacture and market generic mo...
- Aurobindo Pharma, Glenmark get USFDA nod for generic asthma drugAurobindo, Glenmark today said they have received approval from the US health regulator to manufacture, market generic montelukast tablets.
- Indian pharma companies like Aurobindo and Glenmark set to gain from USFDA nod for asthma drugIndian drug makers are set to benefit from a decision by the USFDA to allow sale of generic Singulair tablets used for treating asthma and ...
- Glenmark Pharmaceuticals receives USFDA tentative nod for anti-asthma tabletsGlenmark said it has received tentative approval from the US health regulator to market its tablets used for treating asthma and seasonal a...
Load More
